Right now, someone reading this is carrying a virus in their liver that they are unaware of. No symptoms. No warning. No reason to suspect anything at all. They feel fine. They have felt fine for years. And somewhere inside them, hepatitis B or C is quietly, patiently destroying the organ that keeps them alive.
That is not dramatic language. It is arithmetic. The World Health Organisation estimates that roughly 296 million people worldwide live with chronic hepatitis B, and another 58 million with hepatitis C. In the UK alone, hundreds of thousands of people carry one of these infections without ever having been tested. Most will not discover it until the damage becomes impossible to ignore — cirrhosis, liver failure, or hepatocellular carcinoma. By then, the window for early, effective treatment has already narrowed.
This guide explains hepatitis B and C with the honesty these infections demand. What they do to the liver, how they spread, who is most at risk, why symptoms hide for decades, and how screening and diagnostic equipment give clinicians the power to catch what patients cannot feel. Medigear supplies certified diagnostic and clinical equipment to hospitals and clinics across the UK — because detecting hepatitis early is not a clinical luxury, it is the difference between cure and catastrophe.
Hepatitis B
Hepatitis B is a DNA virus that infects liver cells and triggers an immune response that — paradoxically — causes most of the liver damage. The virus itself does not directly destroy hepatocytes. Instead, the immune system attacks infected cells, creating inflammation that, over the years, leads to fibrosis, cirrhosis, and eventually liver failure or cancer. In adults, roughly ninety-five per cent of acute hepatitis B infections clear spontaneously. The remaining five per cent become chronic — a lifelong infection requiring monitoring and often treatment. In newborns and young children, the numbers invert devastatingly — up to ninety per cent of infant infections become chronic, which is precisely why neonatal vaccination programmes exist.
Hepatitis C
Hepatitis C is an RNA virus with a fundamentally different clinical trajectory. Unlike hepatitis B, acute hepatitis C rarely produces noticeable symptoms — roughly eighty per cent of new infections are completely silent. Of those infected, approximately seventy-five per cent develop chronic infection. Without treatment, chronic hepatitis C progresses through liver fibrosis to cirrhosis over fifteen to thirty years. The transformation that changed hepatitis C from a death sentence to a curable disease happened with direct-acting antiviral therapies — medications that achieve cure rates above ninety-five per cent in eight to twelve weeks of oral treatment. The virus is now curable. The challenge is finding the people who carry it.
How They Spread
Transmission routes differ between the two viruses in ways that matter for screening strategy. Hepatitis B spreads through blood, sexual contact, and mother-to-child transmission during birth. It is significantly more infectious than hepatitis C or HIV, surviving outside the body on surfaces for up to seven days. Hepatitis C spreads primarily through blood-to-blood contact. Sharing needles during injecting drug use remains the dominant transmission route in high-income countries, but unsterile medical procedures, tattooing, and blood transfusions before screening also account for significant numbers. Sexual transmission of hepatitis C occurs but is far less efficient than hepatitis B.
The Symptom Silence
The symptomless nature of both infections makes them so dangerous. Hepatitis B can cause acute illness — fatigue, jaundice, dark urine, abdominal pain — but chronic infection often produces no symptoms for decades. Hepatitis C is even quieter. Patients carry the virus for twenty or thirty years, feeling entirely normal while their liver slowly scars. By the time symptoms emerge — persistent fatigue, unexplained weight loss, abdominal swelling, confusion, bleeding tendencies — cirrhosis is often advanced. The liver does not complain until it is failing.
Risk Factors
Risk factors for hepatitis B include birth in a country with high prevalence, mother-to-child transmission, unprotected sexual contact with an infected partner, sharing needles, occupational needlestick exposure in healthcare workers, and household contact with a chronically infected person. Risk factors for hepatitis C include current or past injecting drug use, receipt of blood products before screening programmes began, unsterile medical or dental procedures — particularly abroad — tattooing or piercing with unsterilised equipment, and HIV co-infection.
Screening
Screening is the only way to find what symptoms hide. A simple blood test detects hepatitis B surface antigen and hepatitis C antibodies — identifying infection in patients who would otherwise remain undiagnosed for years or decades. The UK Health Security Agency recommends opt-out testing in high-prevalence settings — emergency departments, drug treatment services, prisons, and sexual health clinics. GP surgeries serving communities with higher prevalence should actively offer screening rather than waiting for patients to request it. Every undiagnosed infection represents a missed opportunity to prevent liver failure, a missed opportunity to prevent transmission, and a missed opportunity to cure.
Liver Assessment
Liver assessment in diagnosed patients requires equipment that accurately quantifies damage. Transient elastography — commonly known as FibroScan — measures liver stiffness non-invasively, providing a fibrosis score without the need for a liver biopsy. Ultrasound imaging detects structural changes, focal lesions, and signs of portal hypertension. Blood-based fibrosis markers supplement imaging with biochemical assessment. For clinics offering hepatitis screening and management, investing in reliable diagnostic equipment is not optional — it defines the quality and completeness of care. Our complete guide to PCOS symptoms, risks, and diagnosis explains how diagnostic equipment supports complex clinical assessment pathways in ways that translate directly to hepatitis care — structured investigation, reliable imaging, and systematic follow-up protocols.
Treating Hepatitis B
Treatment for hepatitis B focuses on viral suppression rather than cure in most chronic cases. Nucleoside analogue therapy reduces viral load, slows fibrosis progression, and decreases the risk of hepatocellular carcinoma. Treatment is lifelong for many patients and requires regular monitoring of viral load, liver function, and fibrosis status. Functional cure — loss of hepatitis B surface antigen — occurs in a minority of treated patients and remains an active area of research.
Treating Hepatitis C
Treatment for hepatitis C is one of modern medicine's genuine triumphs. Direct-acting antivirals cure the infection in over ninety-five percent of patients regardless of genotype, fibrosis stage, or treatment history. An eight-to-twelve-week oral course with minimal side effects eliminates a virus that previously required interferon-based regimens lasting months with debilitating adverse effects. The barrier to hepatitis C elimination is no longer treatment — it is finding the people who need it.
Prevention
Prevention strategies differ between the two infections. Hepatitis B is vaccine-preventable — one of the most effective vaccines in existence. Universal childhood vaccination, neonatal vaccination for infants born to infected mothers, and catch-up vaccination for at-risk adults form the cornerstone of prevention. Hepatitis C has no vaccine. Prevention relies on harm reduction — needle exchange programmes, supervised consumption facilities, and blood-borne virus awareness education. Both infections benefit from universal precautions in healthcare settings — proper sharps disposal, personal protective equipment, and decontamination protocols that are supported by certified clinical equipment.
Stigma
Stigma remains one of the most destructive forces in hepatitis care. Patients diagnosed with hepatitis B or C frequently face discrimination rooted in assumptions about drug use, sexual behaviour, or immigration status. This stigma delays testing, discourages treatment-seeking, and isolates patients from the support systems they need. Clinics that create non-judgmental screening environments — where testing is routine rather than targeted, and results are delivered with compassion rather than assumption — achieve higher uptake, better treatment engagement, and stronger outcomes. For clinics building comprehensive diagnostic and screening services, our guide to electrosurgical units covering cutting, coagulation, and safety demonstrates how specialist clinical practices approach equipment procurement, safety protocols, and patient-centred care in ways applicable across every clinical discipline.
HIV Co-infection
Co-infection with HIV complicates both hepatitis B and C management significantly. HIV accelerates liver fibrosis progression, alters treatment response, and increases the risk of hepatocellular carcinoma. Patients with HIV should be routinely screened for both hepatitis viruses, and treatment plans must account for drug interactions between antiretroviral and antiviral therapies. Integrated care pathways that address all three infections simultaneously deliver better outcomes than siloed specialist services treating each virus independently.
Point-of-Care Testing
Hepatitis and liver health monitoring increasingly relies on point-of-care testing, bringing screening out of laboratories and into community settings. Rapid diagnostic tests for hepatitis B and C deliver results in minutes from a finger-prick blood sample — enabling testing in pharmacies, mobile clinics, homeless shelters, and drug treatment services where the highest-risk populations are most accessible. This decentralised approach is essential to finding the hundreds of thousands of undiagnosed infections that centralised hospital testing will never reach.
The Elimination Goal
The global push toward hepatitis elimination by 2030 — set by the World Health Organisation — depends entirely on scaling up screening, access to treatment, and vaccination coverage. The UK has made significant progress but remains off-track for elimination targets, primarily because too many infections remain undiagnosed. Every clinic that adds hepatitis screening to its service offering moves the country closer to that goal — one blood test at a time.
Why Choose Medigear
Medigear supplies certified diagnostic and clinical equipment that supports hepatitis screening, liver assessment, and patient management across hospitals, GP surgeries, and community health services throughout the UK. From point-of-care testing devices and ultrasound systems to clinical workflow tools and infection-control equipment, our team helps clinics build the diagnostic capabilities that hepatitis elimination demands. Reach out to our team directly for guidance on equipping your clinic to screen, diagnose, and support hepatitis patients with the thoroughness and compassion this condition deserves.
Conclusion
Hepatitis B and C are among the most consequential infections a person can carry — and among the most likely to go undetected until the damage is already done. The liver does not send warning signals. Symptoms arrive late. And the only defence against decades of silent destruction is a blood test that takes minutes. Clinics that offer routine hepatitis screening do more than diagnose — they intercept liver failure, prevent transmission, and give patients access to treatments that can cure or control what would otherwise quietly kill them. Medigear stands alongside clinical teams with certified diagnostic equipment and a genuine commitment to accelerating hepatitis detection, making it faster, more accessible, and more compassionate. Speak to our team today and help close the gap between the millions who carry hepatitis and the diagnosis that could save their liver — and their life.
DISCLAIMER
The information provided in this guide is for educational and informational purposes only and does not constitute medical advice, clinical recommendation, or professional consultation. Always consult qualified healthcare professionals for clinical decisions regarding hepatitis testing, diagnosis, and treatment. Medigear.uk provides certified medical equipment but does not offer clinical, diagnostic, or treatment advice. Product specifications, availability, and certifications may change — always verify current details with the Medigear team before purchasing.
